comparemela.com

Latest Breaking News On - Prnewswire almirall - Page 1 : comparemela.com

Almirall, S A : Almirall opens a new subsidiary for the Czech Republic and Slovakia

The company is appointing David Festa as General Manager of the Czech Republic and Slovakia affiliate The new affiliate responds to Almirall's expansion strategy to support the company's gradual

Slovak republicUnited statesCzech republicComunidad autonoma de catalunaDavid festaPaolo cioniniPrnewswire almirallEu internationalGeneral managerSlovakia general managerChief commercial officer

Almirall s Klisyri® (tirbanibulin) receives strong recommendation in American Academy of Dermatology AK guideline update

/PRNewswire/ Almirall, LLC, a global biopharmaceutical company focused on skin health, announced its microtubule inhibitor ointment, KLISYRI®.

United statesComunidad autonoma de catalunaPablo alvarezBrian bermanAmerican academy of dermatology focusedPrnewswire almirallSpanish stock exchangeUniversity of miami miller school medicineFocused updateProfessor emeritusMiami miller schoolFull prescribing informationActinic keratosisNoble purposeEngland journal

Almirall achieves Core Net Sales growth of 5 1% to 436 6 MM Euros in H1

Strong operational performance during the first half of the year. The business continues to perform well boosted by the growth in Core Net Sales (+5.1%.

Comunidad autonoma de catalunaPrnewswire almirallEli lillyCore net salesMedical dermatologyScore netNet debtDeferred incomeNet sales

Almirall: Eight out of Ten Patients Maintained Skin Clearance at One Year in Lebrikizumab Atopic Dermatitis Monotherapy Trials

/PRNewswire/ Almirall S.A. (BME: ALM) today announced topline results from one-year analyses of the efficacy and safety of lebrikizumab, an investigational.

New yorkUnited statesComunidad autonoma de catalunaPrnewswire almirallEli lillyKarl ziegelbauerEuropean unionEuropean medicines agencyDrug administrationSpanish stock exchangeChief scientificLotus mallbrisMarketing authorization applicationEczema areaSeverity indexInvestigator global assessment

Almirall, S A : Almirall: Eight out of Ten Patients Maintained Skin Clearance at One Year in Lebrikizumab Atopic Dermatitis Monotherapy Trials

80% of lebrikizumab responders maintained improvements in skin clearance and disease severity at 52 weeks; lasting improvements in itch were also observedData supported both once every two week

New yorkUnited statesComunidad autonoma de catalunaPrnewswire almirallEli lillyKarl ziegelbauerEuropean unionEuropean medicines agencyDrug administrationSpanish stock exchangeChief scientificLotus mallbrisMarketing authorization applicationEczema areaSeverity indexInvestigator global assessment

vimarsana © 2020. All Rights Reserved.